GH Strategies offers CTD/eCTD dossier compilation and registration support that ensures medicines and pharmaceuticals products is not only compliant, but inspection-ready, strategically positioned, and technically defensible.
What GH Strategies Delivers
Regulatory Strategy Built for Approval
We map your product’s regulatory pathway, define data needs early, and eliminate preventable deficiencies before they reach regulatory reviewers.
End-to-End CTD & eCTD Dossier Development
Our team compiles and structures Modules 1–5 using globally validated CTD/eCTD standards that support faster navigation and fewer technical queries.
Quality, Clinical & Non-Clinical Data Validation
Every component – from CMC documentation to clinical summaries – undergoes scientific and regulatory review to ensure accuracy, completeness, and alignment with regulatory requirements.
Labelling, PIL & SmPC Compliance
We design, review, and align all product information to regulatory specifications, ensuring traceability across your entire dossier.
Regulatory Liaison & Query Management
GH Strategies manages your communication with regulatory to provide clarity, prepare responses, and maintain alignment throughout the review cycle.
Lifecycle Management & Post-Approval Support
We continue beyond approval with renewals, variations, product updates, and regulatory intelligence that strengthens long-term compliance.
Not sure if your dossier meets regulatory expectations?
Speak to an Expert.
Regulatory-Compliant CTD & eCTD Excellence
Our dossier designs follow internationally harmonised CTD guidelines, ensuring your administrative, quality, non-clinical, and clinical components are structured for regulator clarity and efficient review.
We use recognised eCTD-authoring software that checks link integrity, folder architecture, XML structure, and metadata to reduce technical rejection risks.
We perform full cross-referencing, ensuring that Module 3 CMC data, Module 4 non-clinical summaries, and Module 5 clinical evidence tell a consistent and scientifically justified story.
All specifications, stability data, process validation summaries, risk assessments, and biostudy documentation are reviewed against SAHPRA’s evolving expectations.
Why CTD & eCTD Submissions Matter
Regulatory authorities worldwide prioritise dossiers that follow global CTD and eCTD standards, ensure data integrity, and demonstrate effective lifecycle control.
A compliant CTD/eCTD submission directly impacts approval timelines, number and complexity of deficiency letters, regulatory confidence in product quality, and market entry strategy and competitiveness.
GH Strategies ensures your submission is built for a successful first-cycle review.
Frequently Asked Questions (FAQs)
Most regulators accept both formats; however, eCTD is increasingly preferred due to improved navigation, lifecycle management, automated validation, and reduced technical deficiencies.
You will need GMP evidence, validated CMC documentation, bioequivalence or clinical data (where required), product information, and administrative documents.
Ideally 3–6 months before intended submission, allowing time for data alignment, gap closure, and quality reviews.
Yes, we regularly reconstruct incomplete or rejected dossiers and realign them with CTD/eCTD requirements.
Common issues include incorrect Module 3 structure, inconsistent cross-referencing, missing hyperlinks, incomplete stability packages, and metadata or lifecycle errors.
Yes. We prepare responses, justification letters, and updated CTD/eCTD sequences required during regulatory review and post-submission lifecycle management.
Let’s Build Something That Lasts
Strengthen your submission with a full CTD/eCTD readiness review.